Galectin-9 Formulation Stabilization with Histidine Buffer and Excipients
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations for recombinant galectin-9 protein lack stability, leading to potential denaturation, oxidation, aggregation, and degradation, which compromises efficacy and may cause adverse effects.
Innovation Solution
A pharmaceutical formulation comprising recombinant stabilized galectin-9 protein, a buffer, and a stabilizer, specifically using histidine acetate buffer with trehalose and mannitol, to enhance stability and maintain carbohydrate recognition activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical formulations are used for recombinant galectin-9 protein, then the formulation can be prepared and administered, but the protein stability is insufficient leading to denaturation, oxidation, aggregation, and degradation
Solution Approach 1:
The patent introduces stabilizing agents (excipients) as intermediary substances that mediate between the protein and the formulation environment. These stabilizers act as protective intermediaries that prevent direct harmful interactions between the protein and destabilizing factors in the formulation, thereby reducing denaturation, oxidation, aggregation, and degradation while maintaining protein stability
Solution Approach 2:
The patent optimizes formulation parameters including pH, ionic strength, and excipient concentrations to create optimal stability conditions. By carefully adjusting these parameters and selecting appropriate stabilizing agents, the formulation achieves enhanced protein stability without compromising the ability to prepare and administer the therapeutic product
2Reliability
If formulation parameters are optimized to improve protein stability, then stability and efficacy are enhanced, but formulation development complexity increases
Solution Approach 1:
The patent systematically optimizes formulation parameters such as pH, buffer composition, and excipient concentrations to achieve optimal protein stability. This parameter optimization approach enhances formulation stability and efficacy while providing a structured methodology that manages development complexity through deliberate parameter selection and adjustment
3Reliability
If stabilizing agents are added to the formulation, then protein stability is improved, but the formulation composition becomes more complex
Solution Approach 1:
Stabilizing agents are introduced as intermediary substances that protect the protein from destabilizing factors. These excipients serve as mediators between the protein and the formulation environment, enhancing protein stability while their selection and optimization provide a systematic approach to managing formulation composition complexity
Solution Approach 2:
The formulation employs composite composition by combining the recombinant galectin-9 protein with multiple stabilizing agents and buffers. This composite approach creates a synergistic formulation where different components work together to enhance protein stability, with the complexity of composition managed through systematic selection and optimization of compatible excipients
Data Source
AI summary
The present invention relates to a stabilized pharmaceutical formulation comprising a recombinant stabilized galectin-9 protein. More specifically, the invention provides a pharmaceutical formulation with improved stability through the combination of a buffer and a stabilizer.